0000921895-19-000997.txt : 20190502 0000921895-19-000997.hdr.sgml : 20190502 20190402215214 ACCESSION NUMBER: 0000921895-19-000997 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PLx Pharma Inc. CENTRAL INDEX KEY: 0001497504 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271707962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 8285 EL RIO STREET STREET 2: SUITE 130 CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: (713) 842-1249 MAIL ADDRESS: STREET 1: 8285 EL RIO STREET STREET 2: SUITE 130 CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: Dipexium Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20140313 FORMER COMPANY: FORMER CONFORMED NAME: Dipexium Pharmaceuticals, LLC DATE OF NAME CHANGE: 20100726 CORRESP 1 filename1.htm

PLx Pharma Inc.
8285 El Rio Street, Suite 130

Houston, Texas 77054

 

 

April 2, 2019

 

VIA EDGAR

 

United States Securities and Exchange Commission
Division of Corporation Finance

Mail Stop 4720
100 F Street, N.E.
Washington, D.C. 20549

Attention: Sonia Bednarowski

 

Re:PLx Pharma Inc.
Registration Statement on Form S-3
Filed March 25, 2019
File No. 333-230478

 

Ladies and Gentlemen:

 

The undersigned Registrant under the above-referenced Registration Statement hereby requests acceleration of the effective date of the Registration Statement to April 4, 2019 at 4:00 p.m., New York time, or as soon thereafter as practicable.

 

We acknowledge that should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and the Registrant may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

We request that we be notified of such effectiveness by a telephone call to Robert H. Friedman of Olshan Frome Wolosky LLP, counsel to the Registrant, at (212) 451-2220 and that such effectiveness also be confirmed in writing.

 

  Very truly yours,
   
  PLx Pharma Inc.
   
  By:

/s/ Rita O’Connor

    Rita O’Connor
    Chief Financial Officer